CME credits were approved by the Mercer Medical School


Cancer Biology and Immunotherapy

Savannah, Georgia | March 30-April 01, 2020
Venue: The DeSoto Savannah | Savannah, GA 31401, USA

Postponement of the Cancer Biology and Immunotherapy Congress, Savannah, GA!

Dear All:

I am sorry to announce that it is no longer safe or feasible to hold the Cancer Biology and Immunotherapy Conference in Savannah, GA., USA on March 30 to April 1, 2020. The status of the global pandemic of the Corona Virus 19 is now critical. The subsequent postponement of the conference is a result of the institution-imposed travel restrictions on the congress faculty and the immigration policy of Europeans to the USA announced by President Trump last evening. I urge you all to adjust your schedules accordingly and I apologize for the inconvenience. As to rescheduling the conference, we will propose a new date soon and I would welcome any suggestion you would find convenient.

With regards to the publication of the special focus in Human Vaccines and Immunotherapeutics, I would still prefer to keep the current deadline of June 1 to July 1, 2020. Certainly, the meeting will be held by this time frame and the publication with the manuscripts and condensed panel discussions, will still come out after the congress. In the meantime, stay well and strong during this health crisis, protect you loved ones and I look forward to the reformation of the congress as soon as possible.
For more information, please contact


Michael G. Hanna Jr., PhD
Chairman, Organizing Committee
Cancer Biology, Immunotherapy Congress
Savannah, Georgia, USA

Plenary Speakers

Conference Schedule

Monday March 30, 2020

  • 8:30-9:00 Welcome and Introductions

  • Dr. Wayne C. Glasgow, Senior Vice Provost for Research, Mercer University
  • Dr. J. David Baxter, Senior Associate Dean Savannah, Mercer University School of Medicine
  • Dr. Michael G. Hanna Jr., Per-Immune Inc., Savannah, GA
  • Plenary Session 1: Cancer biology, pathology and metastasis

  • 9:00-9:40 Dr. Julie Magarian Blander, Cornell University, New York, NY
  • Innate immunity in immunotherapy, macrophages and dendritic cells

  • 9:40-10:20 Dr. J J O’leary, Trinity College, Dublin, Ireland
  • Cancer pathology and tumor growth kinetics, metastasis and tumor cell-stroma relationships

  • 10:20-11:00 Dr. Heyu Ni, University of Toronto, Toronto, Canada
  • The roles of blood platelets in cancer: immune response, metastasis and cancer-related thrombosis

  • 11:00-11:20Coffee Break

  • 11:20-12:00 Dr. Michael Hwang, Johns Hopkins Medical Institute, Baltimore, MD
  • Mutations in oncogenes and tumor suppressor genes drive tumorigenesis: MANA bodies TCR-mimic antibodies for cancer therapy

  • 12:00-12:40 Dr. Joshua L. Hood, University of Louisville, KY
  • Exploring tumor exosome induction of macrophage polarity and therapeutic potential in the context of immune suppression

  • 12:40-01:00 Panel Discussion

  • 1:00-2:00 Lunch

  • Plenary Session 2: Passive immunotherapy

  • Moderator: Dr. Jason David Howard, Sanofi-Genzyme, Cambridge, MA
  • 2:00-2:40 Dr. Jason David Howard, Sanofi-Genzyme, Cambridge, MA
  • Passive immunotherapy in advanced disease cancer patients

  • 2:40-3:20 Dr. Christopher E. Rudd, University of Montreal, Quebec, Canada
  • GSK-3 Inactivation synergizes with PD-1/PL1 and CTLA-4 blockade in cancer immunotherapy

  • 3:20-3:50Coffee Break

  • 3:50-4:30 Dr. Keith Knutson, Mayo Clinic, Jacksonville, FL
  • Immunotherapy beyond checkpoint

  • 4:30-5:10 Dr. Michael Lotze, UPMC Hillman Cancer Center, Pittsburgh, PA
  • Adoptive cell therapies for cancer: focus on tumor infiltrating lymphocytes

  • 5:10-5:50 Dr. Ugo Rovigatti, University of Florence, Italy
  • From anti-GD2 passive immunotherapy in High-Risk Neuroblastoma (HR-NBL) to a new landscape of genomic aberrations and immunotherapy targets

  • 5:50-6:30 Panel discussion

Tuesday March 31, 2020

  • Plenary Session 3: Cancer immunoprevention

  • 8:30-9:10 Dr. Hideho Okada, University of California San Francisco, CA
  • Vaccine approaches for patients with low-grade glioma aimed at prevention of malignant transformation

  • 9:10-9:50 Dr. Vincent K. Tuohy, Cleveland Clinic, Lerner Institute, Cleveland Ohio
  • Primary immunoprevention of adult onset cancers

  • 9:50-10:30 Coffee Break

  • 10:30-11:10 Dr. Olivera Finn, University of Pittsburgh, Pittsburgh, PA
  • Vaccines for the prevention of non-viral cancers

  • 11:10-12:00 Panel discussion

  • 12:00-1:00 Lunch

  • Plenary Session 4: Active specific immunotherapy

  • Moderator: Dr. Robert Dillman, AIVITA Biomedical, Irvine, CA
  • 1:00-1:40 Dr. Robert Dillman, AIVITA Biomedical, Irvine, CA
  • Evolution of therapeutic cancer vaccines

  • 1:40-2:20 Dr. Michael G. Hanna Jr., Per-Immune Inc., Savannah, GA
  • Unlocking The Potential of Personal Cancer Vaccines: The Clinical Ramifications of Antigen Competition Driven Immunoediting

  • 2:20-2:50Coffee Break

  • 2:50-3:30 Dr. J. Milburn Jessup, Veterans Administration Medical Center, Washington, DC
  • Immunogenic cell death is an agnostic adaptive immunity primer for solid tumors

  • 3:30-4:10 Dr. F. Guirakhoo, GeoVax Inc. Atlanta, GA
  • MVA-VLP as a safe and effective platform for delivery of multi-antigen vaccine candidates for infectious diseases and cancer

  • 4:10-5:00 Panel Discussion

Wednesday April 1, 2020

  • Plenary Session 5: Cancer immunotherapy monitoring, methodology and drug design

  • Moderator: Dr. Peter Nara, Keystone Bio Inc., St. Louise, MO
  • 8:30-9:10 Dr. Peter Nara, Keystone Bio Inc., St. Louise, MO
  • Cancer treatment monitoring and drug design

  • 9:10-9:40 Dr. Richard G. Pestell, Pennsylvania Cancer and Regenerative Medicine Center, PA
  • Cancer Stem cells (CSC). Genetic drivers and therapeutic targeting via a new receptor

  • 9:40-10:10 Dr. Martin D’Souza, School of Pharmacy, Mercer Medical School, Atlanta, GA
  • Cancer nano-vaccines delivered via “Band-Aid Like” microneedle patches

  • 10:10-10:30 Coffee Break

  • 10:30-11:00 Dr. Joanna Roder, Biodesix, Boulder, CO
  • Application of machine learning to proteomic datasets: What can AI tell us about immune phenotypes from measurements of the circulating proteome?

  • 11:00-11:30 Dr. Karen A. Norris, University of Georgia, Athens, GA
  • Immunity and immunization in the immunocompromised host

  • 11:30-12:00 Dr. Pavan Muttil, The University of New Mexico, Albuquerque, NM
  • A pulmonary delivery approach to administer combination therapies against lung cancer: are animal models a bane or a boon?

  • 12:00-12:30 Panel Discussion

  • 12:30-1:30 Lunch and Meeting Closure

About CBI-2020

To date, the passive immunotherapeutic approaches which have been FDA-approved clearly provide clinical benefit to a proportion of advanced disease patients. While these treatments have been heralded as much needed improvements, the nearly 600,000 Americans who died of cancer last year did not gain the level of benefit we would have hoped from modern cancer care. As the frontiers of cancer immunotherapy are pushing forward, we need to concentrate on integrative translational medicine. We are proposing to have an outlet for a comprehensive discussion, which will simultaneously integrate a deep understanding of the biology of cancer along with the development of future treatment concepts to ultimately realize the full potential of this clinical revolution.

Learn more
about image

About Janus

JanusJanus was the Roman god of beginnings and transitions. It is depicted as a two-faced image that looks to the future and the past. As first pointed out by Dr. Olivera Finn, the Janus principle can be used to illustrate the past accomplishments and future opportunities in Immunotherapy of Cancer. In this case, immune function/tumor rejection and immune dysfunction/tumor progression. Ann Oncol 2012 Sep 23 (Suppl 8).


Early Bird